ATC Group: A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting

Anatomical Therapeutic Chemical Classification System

Translations

Language
Translation
  English
Insulins and analogues for injection, intermediate-acting combined with fast-acting

Hierarchical Position

Level
Code
Title
4
A10AD
Insulins and analogues for injection, intermediate-acting combined with fast-acting

Contents

Active Ingredients

Chemical substance
Description

The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.

The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.

The primary activity of insulin lispro is the regulation of glucose metabolism.